WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 9'8501 Infant (under 12 months) mortality rate: 152
GDP / capita (US$): 15'3591 Child (under 5 years) mortality rate: 162

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 207'653  205'962  204'213  202'409  200'561  175'288  149'352  121'160 
Births 2'940  2'966  2'988  3'007  3'022  3'538  3'731  3'894 
Surviving infants 2'899  2'924  2'944  2'961  2'974  3'428  3'550  3'590 
Pop. less than 5 years 14'919  14'875  14'928  14'950  14'970  17'572  17'965  17'026 
Pop. less than 15 years 45'967  46'363  46'897  47'429  47'956  52'797  52'960  46'453 
Female 15-49 years 57'016  56'770  56'470  56'133  55'762  48'462  38'886  30'190 

Number of reported cases

(Click for retrospective incidence data for Brazil)
Diphtheria
ChartChart
  12  46  640  4'646 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  214  876  220  36  61'435  99'263 
Mumps
ChartChart
 
Pertussis
ChartChart
  1'208  2'920  8'338  5'211  5'400  764  15'329  45'752 
Polio*
ChartChart
  1'342 
Rubella
ChartChart
  8'781 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  34  298 
Tetanus (total)**
ChartChart
  224  273  273  213  314  346  1'547  3'098 
Yellow fever
ChartChart
  43  85  27 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Brazil)
Vaccine year result method % card seen                                                
BCG 1995  93  DHS   79  96  99*  99*  99*  99*  99*  79  56 
DTP1 1995  95  DHS   79  95  97  99*  99*  99*  99* 
DTP3 1995  81  DHS   79  89  96  93  97  95  98  66  37 
DTP4          61  86  85 
IPV1          99*  97  99*  99* 
HepB_BD          82  91  88  39  99* 
HepB3          89  96  96  99*  96  94 
Hib3          89  96  95  98  95  90 
JapEnc         
MCV1          95  96  99*  99*  99  99*  78  57 
MCV2          77  80  89  69  70  95 
MenA         
PCV1          95  99*  99  97 
PCV2          94  96  94  95 
PCV3          84  94  93  94  88 
Pol3 1995  81  DHS   79  72  98  96  99*  96  99*  58  69 
Rota1          91  99*  91  99 
RotaC          88  94  92  93  86 
RCV1          95  96  99*  99*  99 
TT2plus 1995  45  DHS   79  61  43  38  54  99* 
PAB          99*  43 
VAD1         
YFV          43  99  99*  99*  99*  99* 
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Brazil)
BCG
ChartChart
  99  99  99  99  99  99  79  56 
DTP1
ChartChart
  89  97  98  98  99  99  86  62 
DTP3
ChartChart
  86  96  93  97  95  98  66  37 
HepB3
ChartChart
  86  96  96  96  96  94 
HepB_BD
ChartChart
  91  91  88  89  90  99 
Hib3
ChartChart
  86  96  95  98  95  90 
IPV1
  80  97 
MCV1
ChartChart
  96  96  97  98  99  99  78  57 
MCV2
ChartChart
  72  80  89  69  70  95 
PCV3
ChartChart
  94  94  93  94  88 
Pol3
ChartChart
  98  98  96  96  96  99  58  69 
RCV1
ChartChart
  96  96  97  98  99  99 
RotaC
ChartChart
  94  94  92  93  86 
YFV
ChartChart
  39  46  47  45  42  37 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 5'570  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 59
From 80 to 89% 15
From 50 to 79% 20
Less than 50% 6
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
CHOLERA >= 18 years (x2 doses); Yes Military
DT 2, 4, 6, 15 months; 4 years; Yes risk groups
DTaPHepBIPV private sector
DTaPHibHepIPV private sector
DTwP 15 months; 4 years; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HepA 15 months; Yes for risk groups
HepB_Adult >= 7 years (x3 doses); Yes
HepB_Pediatric birth; Yes
Hib 2, 4, 6 months; Yes Special groups
HPV 9-26 years; +6 months; Yes
Influenza_Adult >= 9 years; Yes and adults with chronic diseases, pregnant women, health care workers and other risk groups
Influenza_Pediatric 6 months to 5 years (x2 doses); Yes and chronic diseases
IPV 2, 4 months; Yes and a dose at 6 months for risk groups
MenACWY private sector
MenB private sector
MenC_conj 3, 5, 12 months; Yes '
MMR 12 months; Yes
MMRV 15 months; Yes
OPV 6, 15 months; 4 years; Yes
Pneumo_conj 2, 4, 6, 12 months; Yes
Pneumo_ps 5 years; Yes elderly and risk groups
Rotavirus 2, 4 months; Yes
Td 1st contact; +2, +4 months; Yes >7 years
Tdap Yes For each pregnancies (between week 27 to 36)
Varicella 15 months; Yes if not given in combination vaccine with MMR
YF 9 months; 4 years; No where indicated

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2014-2018  2012-2015    2011-2016  2011-2015    2008-2011 
Nº of districts with microplans that include activities to raise immunization coverage number       5'567  5'565     

System performance

Total Nº districts in country number 5'570  5'570  5'570  5'565  5'565  5'565  5'565 
Nº districts with DTP3 coverage >=80% number 4'134  4'688  4'639  4'658  4'616  4'950  4'951 
% of districts with DTP3 coverage >=80% From 0 to 100% 74  84  83  84  83  89  89 
Nº districts with measles (MCV1) coverage >=95% number 3'259  3'204  4'284  4'194  3'413  3'369  3'354 
% of districts with MCV1 coverage >=95% From 0 to 100% 59  58  77  75  61  61  60 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 88  100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.